Healthpeak Properties and Pfizer offer dividend yields above 6% and have good reasons to expect payout raises. Healthpeak Properties is a healthcare REIT with a diversified portfolio and a 10.1% tenant in HCA Healthcare. Pfizer is America's largest drugmaker with a growing dividend payout every year since 2009. Both stocks offer attractive options for everyday investors looking to grow their passive income stream.
Healthpeak Properties (DOC) and Pfizer (PFE) are two stocks that have caught the attention of income-seeking investors due to their attractive dividend yields and potential for payout raises. Both companies offer high yields, making them appealing options for everyday investors looking to grow their passive income.
Healthpeak Properties
Healthpeak Properties is a healthcare-related real estate investment trust (REIT) that expanded its portfolio through a merger with Physicians Realty Trust. The combined entity focuses on laboratories and medical office buildings, providing a diversified income stream. At the end of March, health systems and physician groups were responsible for 55% of annualized base rent, while drugmakers accounted for another 34%. HCA Healthcare, a publicly traded hospital operator, is the REIT's largest tenant, contributing 10.1% of annualized rent [1].
Management expects funds from operations (FFO) to land in a range between $1.81 and $1.87 per share this year, which is more than enough to support increasing dividend payouts. The REIT's dividend payout is currently set at an annualized $1.22 per share. With annual rent escalators written into long-term leases, investors can expect a steady increase in the REIT's dividend payout over the long run [1].
Pfizer
Pfizer, America's largest drugmaker, has seen its stock price decline by about 60% from its 2021 peak. However, income-seeking investors have been doing well with the stock, as its dividend payout has grown every year since 2009. At its current price, the stock offers an eye-popping 6.9% dividend yield [1].
Pfizer's dividend payout is expected to remain steady, with management planning to reinvest much of its COVID-19 windfall into a productive development pipeline. The company expects new products to deliver $20 billion in annual revenue by 2030, which could help offset the impact of patent cliffs. In addition, Pfizer's acquisition of Seagen in 2023 has given it access to several blockbuster cancer therapies, which could drive future growth [1].
Conclusion
Healthpeak Properties and Pfizer offer attractive dividend yields and potential for payout raises, making them appealing options for everyday investors looking to grow their passive income. Both stocks have good reasons to expect payout raises in the near term, with Healthpeak Properties' diversified portfolio and Pfizer's growing dividend payout every year since 2009 providing strong support for their dividend growth prospects.
References
[1] https://finance.yahoo.com/news/2-reliable-dividend-stocks-yields-082700425.html
[2] https://www.nasdaq.com/articles/5-stocks-10-average-yield-and-60-dividend-checks-year
Comments
No comments yet